The clinical and pathological features of plasma cell myeloma post solid organ transplantation
Autor: | Suzanne Lentzsch, David C. Park, Rebecca J. Leeman-Neill, Govind Bhagat, Bachir Alobeid, George Vlad, Kenneth Ofori, Craig R. Soderquist, Vundavalli V. Murty |
---|---|
Rok vydání: | 2020 |
Předmět: |
Adult
Male medicine.medical_specialty medicine.medical_treatment Lymphoproliferative disorders Plasma cell Gastroenterology Disease-Free Survival Leukemia Plasma Cell 03 medical and health sciences 0302 clinical medicine Immunophenotyping Internal medicine Plasma Cell Myeloma medicine Humans Lung transplantation Multiple myeloma Aged business.industry Organ Transplantation Hematology Middle Aged Plasma cell neoplasm medicine.disease Survival Rate Transplantation medicine.anatomical_structure 030220 oncology & carcinogenesis Female business Follow-Up Studies 030215 immunology |
Zdroj: | American Journal of Hematology. 95:1531-1541 |
ISSN: | 1096-8652 0361-8609 |
DOI: | 10.1002/ajh.25988 |
Popis: | Plasma cell neoplasms (PCNs), comprising plasma cell myelomas (PCMs) and plasmacytomas, occurring after solid organ transplantation, represent rare subtypes of monomorphic post-transplant lymphoproliferative disorders (M-PTLDs). Data regarding the clinical and pathological features of post-transplant (PT)-PCMs are limited. To gain a better understanding of disease biology, we performed comprehensive immunophenotypic analysis, reviewed cytogenetic analysis results and evaluated clinical outcomes of PT-PCMs diagnosed and treated at our institution. Fifteen PT-PCM (M: F - 4:1) and 2 PT-MGUS (2 males) cases were identified. The median age of PT-PCM patients was 68yrs (29-79 yrs) and PCMs presented at a median of 9.7yrs (0.5-24.7 yrs) after transplantation. PT-PCMs accounted for 11.6% of all M-PTLDs and the period prevalence was 9/3108 (0.29%), 3/1071 (0.28%), 2/1345 (0.15%) and 1/878 (0.11%) post kidney, heart, liver and lung transplantation. Lytic bone disease was observed in 1/11 (9%) patients. Marrow plasma cell infiltration ranged from 10%-70% (median 20%), with 10/15 (67%) and 5/15 (33%) cases manifesting immature and plasmablastic morphology. The immunophenotype of all cases and cytogenetic abnormalities, identified in 60% of cases, were similar to multiple myeloma (MM) of immunocompetent individuals. All PT-PCMs were EBER-. Ten of 11 (91%) patients with active MM were treated, all with proteasome inhibitor-based therapy. Treatment response and 5-year overall survival (54.5%) was comparable to MM of immunocompetent individuals. However, the survival of patients with plasmablastic PCMs was inferior to those with immature PCMs. 0ur findings indicate PT-PCMs to be predominantly late onset PTLDs that have similar clinicopathologic characteristics as conventional MM. This article is protected by copyright. All rights reserved. |
Databáze: | OpenAIRE |
Externí odkaz: |